Genetic variants of interferon regulatory factor 5 associated with chronic hepatitis B infection

Table 4 Haplotype distribution among chronic hepatitis B virus carriers and the association of IRF5 haplotypes with hepatitis B virus-infected liver diseases n (%)

Haplotypes	HC,n = 484	CHB,n = 198	LC,n = 298	HCC,n = 262	LC vs CHB		HCC vs CHB		HCC vs LC
					OR (95% CI)	P value	OR (95% CI)	P value	OR (95%CI)	P value
ACAC	196 (40.6)	83 (41.9)	98 (37.4)	132 (44.3)	Reference		Reference		Reference
TCGT	141 (29.0)	37 (18.7)	86 (32.7)	81 (27.2)	2.1 (1.2-3.3)	0.008		NS	0.7 (0.4-1.1)	0.08
TCAT	33 (6.8)	27 (13.6)	12 (4.6)	13 (4.4)	0.4 (0.2-0.8)	0.037	0.3 (0.15-0.7)	0.003		NS
ACAT	54 (11.2)	24 (12)	30 (11.5)	31 (10.4)		NS		NS		NS
TTAT	49 (10.2)	18 (9.1)	34 (13)	33 (11.1)		NS		NS		NS
ACGC	2 (0.4)	1 (0.5)	0 (0)	1 (0.3)		NS		NS		NS
ACGT	5 (1)	5 (2.5)	1 (0.4)	3 (1)		NS		NS		NS
TCGC	2 (0.4)	0 (0)	1 (0.4)	0 (0)		NS		NS		NS
TTGT	2 (0.4)	3 (1.5)	0 (0)	4 (1.3)		NS		NS		NS

HCC: Hepatocellular carcinoma. Comparison between HC vs HBV patient group did not indicate any significant difference (data not shown in this table). OR and P values were calculated by using binary logistic model adjusted for age and gender, CHB: Chronic hepatitis B; LC: Liver cirrhosis.